aMoon Fund

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Lutris Pharma is an Israel-based biopharmaceutical company focused on improving anti-cancer therapy. It develops drugs to enhance treatment effectiveness, including a proprietary topical B-Raf inhibitor LUT014 that enables administration of epidermal growth factor receptor inhibitors without the cutaneous side effects that typically interrupt therapy. Founded in 2015 and based in Tel Aviv-Yafo, Lutris Pharma aims to improve treatment continuity and patient quality of life for those treated with EGFR inhibitors.

Lyfegen is a global, independent provider of drug access, pricing and rebate management solutions, headquartered in Basel, Switzerland, with offices in Boston, USA. The company offers software and services to help healthcare payers and pharmaceutical companies identify appropriate price agreements, simulate and understand the financial impact of those agreements, and automate the execution and adjudication of rebates, reducing administrative effort. By enabling more efficient rebate management, Lyfegen aims to improve patient access to therapies, affordability, and overall health outcomes.

MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

Air Doctor Ltd. operates an online marketplace that connects travelers with verified healthcare professionals in various locations. Founded in 2016 and based in Motza Illit, Israel, the platform allows users to search for and schedule appointments with doctors, dentists, emergency clinics, pharmacies, and other healthcare specialists. By providing access to practitioner profiles and patient reviews, Air Doctor simplifies the process of obtaining medical care abroad, ensuring that users can find professionals who speak their language and meet their specific needs. This service aims to enhance the experience of travelers by making healthcare access straightforward and efficient in unfamiliar destinations.

Hopscotch Primary Care is a healthcare company focused on transforming rural healthcare through data-driven, team-based care that expands access and improves quality for patients in rural communities. The organization delivers tailored quality care via a collaborative model and provides resources and support for patients inside and outside clinics, enabling clinicians to offer the right care and continuity of service.

AltruBio is a biopharmaceutical company dedicated to the development of targeted antibody therapeutics aimed at treating cancer and immune-related inflammatory diseases. With its research and development foundation established in Taipei, Taiwan, since 2000, the company focuses on addressing unmet medical needs through innovative therapeutic solutions. AltruBio has developed an efficient discovery platform that identifies and validates novel antibody therapeutics. The company is actively advancing several potential therapeutic antibodies that target various conditions, including autoimmune diseases and multiple forms of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers. By leveraging its expertise in antibody-drug conjugate therapy and developing specialized linker payloads, AltruBio strives to improve patient outcomes and enhance recovery from immune-mediated diseases.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Lyfegen is a global, independent provider of drug access, pricing and rebate management solutions, headquartered in Basel, Switzerland, with offices in Boston, USA. The company offers software and services to help healthcare payers and pharmaceutical companies identify appropriate price agreements, simulate and understand the financial impact of those agreements, and automate the execution and adjudication of rebates, reducing administrative effort. By enabling more efficient rebate management, Lyfegen aims to improve patient access to therapies, affordability, and overall health outcomes.

Theranica is a medical device company specializing in the development of electroceuticals that utilize neuromodulation therapy combined with advanced wireless technology. The company has created a proprietary wearable solution, specifically a non-invasive 'smart' patch, designed to address various medical conditions, with a primary focus on migraine headaches. This innovative product is controlled via a smartphone app, allowing for personalized and portable treatment options. The patch features a unique 'smart' chip that delivers electrical pulses to modulate the sensory nerves beneath the skin, offering patients an effective means of managing acute migraines. Theranica's solutions aim to provide affordable care and enhance the quality of life for individuals suffering from neurological pain.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Sera Prognostics, Inc. is a biotechnology company that develops diagnostic tests to predict a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy complications. Using proteomics and bioinformatics, it discovers and commercializes blood-based biomarker tests and predictive analytics to guide early, personalized interventions and reduce healthcare costs associated with pregnancy complications. Founded in 2008 and based in Salt Lake City, Utah, Sera aims to improve maternal and neonatal outcomes by providing physicians with actionable risk information during pregnancy.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

AltruBio is a biopharmaceutical company dedicated to the development of targeted antibody therapeutics aimed at treating cancer and immune-related inflammatory diseases. With its research and development foundation established in Taipei, Taiwan, since 2000, the company focuses on addressing unmet medical needs through innovative therapeutic solutions. AltruBio has developed an efficient discovery platform that identifies and validates novel antibody therapeutics. The company is actively advancing several potential therapeutic antibodies that target various conditions, including autoimmune diseases and multiple forms of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers. By leveraging its expertise in antibody-drug conjugate therapy and developing specialized linker payloads, AltruBio strives to improve patient outcomes and enhance recovery from immune-mediated diseases.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

MiNA Therapeutics Limited is a clinical-stage biotechnology company based in London, United Kingdom, focused on the design and development of small activating RNA medicines aimed at restoring normal cellular function. Founded in 2008, the company is dedicated to harnessing gene activation mechanisms to create therapeutic solutions for cancer and other severe diseases. Its product pipeline includes MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA paired with Pembrolizumab for advanced solid tumors. Through its innovative approach, MiNA Therapeutics aims to transform the treatment landscape, enabling healthcare professionals to effectively address challenging medical conditions.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Founded in 2017, Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel. It develops a three-dimensional tissue culture system for modelling cancer growth and drug response, preserving the cancer's original microenvironment. The company offers an online platform enabling patients and clinicians to send tumor samples for testing, aiming to improve personalized cancer treatment by matching the most effective drugs to individual patients' tumors.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

AposHealth is focused on transforming the treatment of musculoskeletal conditions by addressing gait mechanics to alleviate pain and enhance mobility. Its flagship product, Apos®, is an FDA-cleared device designed to temporarily reduce knee pain associated with osteoarthritis, while also serving as a wellness tool for chronic lower back and hip pain. The Apos® system combines gait analysis with a personalized, foot-worn device and a tailored treatment plan. With a robust track record of over 110,000 patients treated and a 96 percent satisfaction rate, AposHealth is supported by numerous peer-reviewed studies that validate the effectiveness of its approach. By offering a drug-free and non-surgical solution, AposHealth empowers individuals to manage their discomfort and improve their quality of life.

Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTR™ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

NanoGhost is a biotechnology company that specializes in advanced drug-delivery technology aimed at combating aggressive forms of cancer. Founded based on research from the Technion, which has secured patents for its innovation in the U.S. and Europe, NanoGhost utilizes adult stem cells to transport therapeutic agents directly to tumor sites. This targeted approach is designed to effectively shrink tumors, specifically in cases of small lung carcinoma, prostate cancer, and pancreatic cancer. By focusing on precise delivery, the company aims to alleviate pain associated with traditional radiology treatments, ultimately enhancing the quality of life for cancer patients.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Vocalis Health is a health technology company founded in 2019 and based in Tel Aviv, Israel, with an additional office in the United States. The company specializes in developing an artificial intelligence platform that utilizes vocal biomarkers to monitor and diagnose health conditions through voice analysis. Its technology enables healthcare providers to remotely screen and monitor patients affected by various voice-related diseases, including chronic respiratory and cardiac conditions, as well as mental health issues like depression. By employing machine learning and deep learning techniques, Vocalis Health's platform analyzes the acoustic features of voice recordings, providing valuable insights that help assess the severity and presence of health conditions, all accessible via a mobile application or web browser. The company was formed through the merger of Beyond Verbal and Healthymize.

Igentify Ltd is an Israeli company specializing in preventive healthcare through genomic products and services. Founded in 2016 by Galit Delmar and Yagil Tzur, Igentify is headquartered in Haifa. The company focuses on enhancing access to genomic information for clinicians, laboratories, and patients through its end-to-end digital genetic platform. One of its key offerings is FamilyFirst, an expanded carrier screening designed specifically for the Jewish and Israeli populations. Igentify's platform addresses the increasing demand for genomic medicine by digitizing various processes related to genetic testing, including patient education, consent collection, data analysis, and the delivery of personalized results. This approach aims to streamline and simplify the complexities often associated with genomic healthcare.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing small-molecule therapeutics for patients with rare and aggressive cancers, using a bioinformatics platform and next-generation sequencing to identify tumorigenic drivers and guide targeted therapies. The company is developing AL101, an intravenous gamma secretase inhibitor for Notch-activating tumors such as adenoid cystic carcinoma, which is in Phase II, and AL102, an oral gamma secretase inhibitor for desmoid tumors, in Phase I. Ayala has a collaboration with Novartis to advance AL102 for multiple myeloma. Founded in 2017, the company is headquartered in Rehovot, Israel.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Theranica is a medical device company specializing in the development of electroceuticals that utilize neuromodulation therapy combined with advanced wireless technology. The company has created a proprietary wearable solution, specifically a non-invasive 'smart' patch, designed to address various medical conditions, with a primary focus on migraine headaches. This innovative product is controlled via a smartphone app, allowing for personalized and portable treatment options. The patch features a unique 'smart' chip that delivers electrical pulses to modulate the sensory nerves beneath the skin, offering patients an effective means of managing acute migraines. Theranica's solutions aim to provide affordable care and enhance the quality of life for individuals suffering from neurological pain.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

Nobio Ltd. is a biotechnology company based in Petah Tikva, Israel, specializing in the development of innovative nano-polymer additives that provide protection against microbial infections. Its technology enables the transformation of both implantable and non-implantable devices into biofilm-resistant platforms. Nobio's product offerings include a universal bonding agent designed for strong adhesion to various dental surfaces and restorative materials, as well as flowable composites suitable for dental restorations and sealants. The core of Nobio's technology consists of potent particles embedded with highly-active antimicrobial structures that kill bacteria upon contact, effectively preventing medical device contamination indefinitely. This unique approach positions Nobio as a leader in the creation of durable antimicrobial materials and surfaces, enhancing safety and efficacy in medical and dental applications.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Medial EarlySign develops an AI-powered clinical decision support and population health platform that analyzes basic medical information, laboratory results, and electronic medical records to identify patients at risk of serious diseases before symptoms appear. Its predictive engines, including AlgoMarkers and AlgoAnalyzer, are designed to extract prognostic insights from large-scale patient data and integrate person-level risk assessments into clinical workflows, enabling proactive, personalized care management. The platform supports early detection and prediction of outcomes across cancers, metabolic, immune, and infectious diseases, helping healthcare providers diagnose large patient populations, improve diagnostic rigor, and guide preventive interventions. The company was founded in 2009 and is based in Kfar Malal, Israel.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.